Mònica Sánchez-Guixé

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet et al. · Nature Communications · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +16

STUB1 mutations in autosomal recessive ataxias – evidence for mutation-specific clinical heterogeneity

Ketil Heimdal, Mònica Sánchez-Guixé, Ingvild Aukrust et al. · Orphanet Journal of Rare Diseases · 2014 · 73 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana R�os et al. · Cancer Research · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacology +16

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris‐Oliver, Marta Palafox, Laia Monserrat et al. · Clinical Cancer Research · 2020 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>In vitro</i> characterization of six <i>STUB1</i> variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins

Yasaman Pakdaman, Mònica Sánchez-Guixé, Rune Kleppe et al. · Bioscience Reports · 2017 · 30 citations · Full text

Life Sciences, Genetics, Molecular Biology +17